Pharmaceutical

First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and…

12 months ago

TLC to Present at the 42nd Annual JP Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec. 27, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty…

12 months ago

NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208

ORION CORPORATION PRESS RELEASE 27 DECEMBER 2023 at 11:00 EET                      NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208…

12 months ago

Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant

NORTHVALE, NJ / ACCESSWIRE / December 26, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical…

12 months ago

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

$5 million at closing and up to $7 million of additional committed fundingSAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) --…

12 months ago

Zymeworks Announces $50 Million Private Placement to EcoR1 Capital

Proceeds expected to extend cash runway into H2 2027VANCOUVER, British Columbia, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq:…

12 months ago

60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

 Investigational Review Board (IRB) approval has been granted for 60 Degrees Pharma’s double-blind, placebo-controlled study to investigate tafenoquine for treatment…

12 months ago

Harpoon Therapeutics Strengthens Leadership Team

James Bucher, J.D. joins as Chief Legal Officer Wendy Chang promoted to Chief People Officer SOUTH SAN FRANCISCO, Calif., Dec.…

12 months ago

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb’s Leading…

12 months ago

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

MONTREAL and CHARLOTTE, N.C., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) announced today that the Company received…

12 months ago